Want to see HK:1877 full AI Analyst Report?
1877 Stock Chart & Stats
HK$27.54
-HK$0.08(-0.74%)
At close: 4:00 PM EST
HK$27.54
-HK$0.08(-0.74%)
Day’s Range― - ―
52-Week RangeHK$15.25 - HK$38.64
Previous CloseN/A
Volume306.00K
Average Volume (3M)7.63M
Market Cap
HK$36.02B
Enterprise ValueHK$31.99B
Total Cash (Recent Filing)HK$4.55B
Total Debt (Recent Filing)HK$5.96B
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding260,295,700
10 Day Avg. Volume5,398,960
30 Day Avg. Volume7,633,399
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)3.19
Price to Sales (P/S)7.92
P/FCF Ratio-15.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$32.25Price Target Upside17.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.44
Revenue Forecast (FY)HK$3.31B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsVery strong gross margins (~78.7%) indicate favorable product economics typical of biologics. Durable unit-level profitability gives the company scope to fund R&D and commercialization as revenue scales, supporting long-term margin expansion if fixed costs are absorbed.
Sustained Revenue GrowthTTM revenue growth of 8.8% shows sustained commercial traction for marketed products. Consistent top-line expansion provides runway to spread fixed R&D and SG&A, enabling margin improvement and eventual positive operating cash flow while supporting reinvestment and geographic expansion.
Innovative Pipeline & Commercial CapabilityA focused portfolio in immuno-oncology and autoimmune biologics plus in-house R&D and commercialization capabilities creates multiple durable revenue channels (product sales, licensing, services). This structural positioning supports long-term growth and partnership opportunities.
Bears Say
Negative Cash FlowNegative operating cash flow (~-416M TTM) and deeply negative free cash flow (~-1.27B TTM) show ongoing cash burn. This requires external funding or asset monetization, risks dilution, and constrains the pace of commercial scaling and sustained R&D investment until cash generation turns positive.
Sustained UnprofitabilityPersistent negative EBIT/EBITDA and a roughly -35% net margin indicate the company has not converted strong gross margins into operating profit. Continued losses erode retained capital and require meaningful operating leverage or cost reductions to reach breakeven and sustain investor support.
Rising Leverage & Negative ROEDebt-to-equity near 0.69 with leverage rising from prior years, and TTM ROE about -14%, reduce financial flexibility while profitability remains weak. Higher leverage amid losses raises refinancing risk and interest burden, constraining the company's ability to fund growth without adverse balance-sheet moves.
Shanghai Junshi Biosciences Co., Ltd. Class H News
1877 FAQ
What was Shanghai Junshi Biosciences Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Junshi Biosciences Co., Ltd. Class H lowest stock price was HK$15.25 and its highest was HK$38.64 in the past 12 months.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s market cap?
Shanghai Junshi Biosciences Co., Ltd. Class H’s market cap is HK$36.02B.
When is Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date is Aug 27, 2026 which is in 56 days.
How were Shanghai Junshi Biosciences Co., Ltd. Class H’s earnings last quarter?
Shanghai Junshi Biosciences Co., Ltd. Class H released its earnings results on Apr 27, 2026. The company reported -HK$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.023.
Is Shanghai Junshi Biosciences Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Junshi Biosciences Co., Ltd. Class H’s price is currently Undervalued.
Does Shanghai Junshi Biosciences Co., Ltd. Class H pay dividends?
Shanghai Junshi Biosciences Co., Ltd. Class H does not currently pay dividends.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate?
Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Junshi Biosciences Co., Ltd. Class H have?
Shanghai Junshi Biosciences Co., Ltd. Class H has 260,295,700 shares outstanding.
What happened to Shanghai Junshi Biosciences Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Junshi Biosciences Co., Ltd. Class H reported an EPS of -HK$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.773%.
Which hedge fund is a major shareholder of Shanghai Junshi Biosciences Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:1877
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Junshi Biosciences Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$32.25 (17.10% Upside)
HK$32.25 (17.10% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.67%
12-Months-Change
Fundamentals
Return on Equity
-10.78%
Trailing 12-Months
Asset Growth
37.38%
Trailing 12-Months
Company Description
Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical firm focused on the research, creation, and marketing of diverse pharmaceutical products. Operating within the People's Republic of China, its therapeutic focus spans oncology, metabolic disorders, autoimmune conditions, neurological ailments, and infectious diseases. Among its offerings is JS001, marketed as TUOYI, a recombinant humanized anti-PD-1 monoclonal antibody. This treatment is prescribed for a wide array of cancers, including melanoma (both cutaneous and mucosal), soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. The company's development pipeline also includes UBP1211, a biosimilar version of Humira, intended for rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Additionally, they are advancing JS002, a recombinant humanized anti-PCSK9 monoclonal antibody designed to address hyperlipidemia, and UBP1213, an injectable recombinant humanized anti-BLyS monoclonal antibody. Further projects encompass JS501, a biosimilar of Avastin; JS003, an injectable recombinant humanized anti-PD-L1 monoclonal antibody; JS101, which acts as a pan-CDK inhibitor; TAB004/JS004, an injectable recombinant humanized anti-BTLA monoclonal antibody; and JS005, another injectable recombinant humanized anti-IL-17A monoclonal antibody. Furthermore, Junshi Biosciences holds partnerships, including an agreement with Eli Lilly and Company to collaboratively develop therapeutic antibodies aimed at the prevention and treatment of COVID-19, the illness resulting from the SARS-CoV-2 novel coronavirus. Another collaboration is with Coherus Biosciences, Inc. for the advancement and commercialization of toripalimab, which is Junshi Biosciences' anti-PD-1 antibody. Established in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its primary offices in Shanghai, People's Republic of China.
1877 Stock 12 Month Forecast
Average Price Target
HK$32.25
▲(17.10% Upside)
Technical Analysis
Innovent Biologics
―
Zai Lab Ltd
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---